Study S001032

Effect of Semaglutide 2.4 mg Once-weekly on Gastric Emptying in Subjects With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03842202
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 72
Start: 2019-02-15
Primary completion: 2019-11-04
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1215-9915; REGISTRY:2018-002497-42; NIH:2018

Registered primary outcomes

AUC0-5h,para: the area under the paracetamol concentration-time curve from 0 to 5 hours at steady state [0 to 5 hours after standardised meal (day 142)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023297	The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Friedrichsen M, Diabetes, obesity & metabolism	2021	Randomized trial	PMID 33269530 DOI	registry reference RESULT:33269530